Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Epigenetic-Based Cancer Therapeutics: New Potential Hdac8 Inhibitors Publisher Pubmed



Hassanzadeh M1 ; Mahernia S2 ; Caprini G3 ; Fossati G3 ; Adib M4 ; Moakedi F5 ; Amanlou M1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Centre for Research, Italfarmaco, S.p.A, Cinisello Balsamo, Italy
  4. 4. School of Chemistry, College of Science, University of Tehran, Tehran, Iran
  5. 5. Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

Source: Journal of Biomolecular Structure and Dynamics Published:2022


Abstract

Designing dual small molecule inhibitors against enzymes associated with cancer has turned into a new strategy in cancer chemotherapy. Targeting DNA methyltransferase (DNMT) and histone deacetylase (HDAC) enzymes, involved in epigenetic modifications, are considered as promising treatments for a wide range of cancers, due to their association with the initiation, proliferation, and survival of cancer cells. In this study, for the first time, the dual inhibitors of the histone deacetylases 8 (HDAC8) and DNA methyltransferase 1 (DNMT1) has introduced as novel potential candidates for epigenetic-based cancer therapeutics. This research has been facilitated by employing pharmacophore-based virtual screening of ZINC and Maybridge databases, as well as performing molecular docking, molecular dynamics simulations and free binding energy calculation on the top derived compound. Results have demonstrated that the suggested compounds not only adopt highly favorable conformations but also possess strong binding interaction with the HDAC8 enzyme. Additionally, the obtained results from the experimental assay confirmed the predicted behavior of inhibitors from virtual screening. These results can be used for further optimization to yield promising more effective candidates for the treatment of cancer. Communicated by Ramaswamy H. Sarma. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Experts (# of related papers)
Other Related Docs
14. Structure-Based Virtual Screening for Defeating Drug Resistant Form of Egfr Protein, Combinatorial Chemistry and High Throughput Screening (2016)
28. Deregulated Expression of Hdac3 in Colorectal Cancer and Its Clinical Significance, Advances in Clinical and Experimental Medicine (2018)